New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO) Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months...

Renewable Energy Group Statement on Proposed Renewable Volume Obligations AMES, Iowa, July 05, 2017 (GLOBE NEWSWIRE) -- Renewable Energy Group, Inc. (NASDAQ:REGI) President and CEO Randy Howard issued the following statement regarding the Environmental Protection Agency’s...

Clearside Biomedical, Inc. to Present at the 2016 Wedbush PacGrow Healthcare Conference ALPHARETTA, Ga., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...